Search Results - "Guennel, Tobi"

Abstract LB-133: Correlative analysis of pharmacokinetics and pharmacodynamics of RGX-104, a first-in-class Liver-X-Receptor (LXR) agonist, and clinical outcomes in patients with advanced solid tumors by Mita, Monica, Mita, Alan, Hamilton, Erika, Falchook, Gerald S., Postow, Michael, Chmielowski, Bartosz, Schilder, Russell J., Strauss, James, Lim, Emerson, Pant, Shubham, Jain, Angela, Rixe, Oliver, Redman, Rebecca, Kim, Kevin B., Dragovich, Tomislav, Harvey, R. Donald, Puzanov, Igor, Schneider, Nimisha, Deehan, Renee, Guennel, Tobi, Lin, Joe, Tavazoie, Sohail, Waltzman, Roger, Rowinsky, Eric, Szarek, Michael, Sridhar, Subhasree, Busby, Robert, Lebaka, Narayan, Andreu, Celia, Kurth, Isabel, Darst, David, Tavazoie, Masoud, Raza, Syed, Wasserman, Robert, Gonsalves, Foster C.

“…Abstract RGX-104, a first-in-class small-molecule LXR agonist modulates innate immunity and cancer progression via transcriptional activation of ApoE. ApoE…”
Get full text

A genetic enrichment strategy for delay of onset of Alzheimer’s disease clinical trials by Lutz, Michael W., Burns, Daniel K., Alexander, Robert, Culp, Meredith, Yarnall, David, Haneline, Stephen, Chiang, Carl, Lai, Eric, Metz, Craig, Sundseth, Scott, Guennel, Tobi, Marshall, Scott, Andruss, Bernard F., Latham, Gary J., Hall, Bradley, Statt, Sarah N., Swanson, Tom, Ratti, Emiliangelo, Saunders, Ann M.

“…Background A challenge with AD prevention is the timely identification of subjects at risk of cognitive symptom onset, mitigating prohibitive costs associated…”
Get full text

A genetic enrichment strategy for delay of onset of Alzheimer’s disease clinical trials: Biomarkers (non‐neuroimaging)/Use in clinical trial design and evaluation by Lutz, Michael W., Burns, Daniel K., Alexander, Robert, Culp, Meredith, Yarnall, David, Haneline, Stephen, Chiang, Carl, Lai, Eric, Metz, Craig, Sundseth, Scott, Guennel, Tobi, Marshall, Scott, Andruss, Bernard F., Latham, Gary J., Hall, Bradley, Statt, Sarah N., Swanson, Tom, Ratti, Emiliangelo, Saunders, Ann M.

“…Abstract Background A challenge with AD prevention is the timely identification of subjects at risk of cognitive symptom onset, mitigating prohibitive costs…”
Get full text